SCHEMBL1996723

SCHEMBL1996723

COCCNc1ccnc(-c2cnc3ccc(C#N)cn23)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.47
JAK3 P52333 2/20 0.47
CYP1A2 P05177 5/20 0.47
CYP2C19 P33261 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP3A4 P08684 2/20 0.44
EIF2AK4 Q9P2K8 4/20 0.44
GLA P06280 1/20 0.43
CYP2C9 P11712 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
CYP2D6 P10635 1/20 0.43
FLT3 P36888 1/20 0.42
IRAK4 Q9NWZ3 2/20 0.41
IRAK1 P51617 1/20 0.41
FYN P06241 3/20 0.41
KIT P10721 1/20 0.41
MKNK1 Q9BUB5 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1994326 0.85 JAK2 (0.50) JAK2JAK3EIF2AK4FLT3IRAK4
SCHEMBL1997645 0.84 EIF2AK4 (0.45) JAK2JAK3EIF2AK4FLT3IRAK4
SCHEMBL12643877 0.84 CYP1A2 (0.49) CYP1A2CYP2C19ALDH1A1ALOX15HIF1A
SCHEMBL2000446 0.81 KIT (0.60) JAK2CYP1A2CYP2C19ALDH1A1ALOX15
SCHEMBL1993309 0.80 KIT (0.47) JAK2CYP1A2CYP2C19ALDH1A1ALOX15
SCHEMBL1994074 0.80 EIF2AK4 (0.49) JAK2JAK3CYP3A4EIF2AK4FLT3
SCHEMBL1998769 0.80 KIT (0.53) JAK2CYP1A2CYP2C19ALDH1A1ALOX15
SCHEMBL1993894 0.79 IRAK4 (0.46) JAK2JAK3EIF2AK4FLT3IRAK4
SCHEMBL1992847 0.77 EIF2AK4 (0.45) JAK2JAK3CYP3A4EIF2AK4FLT3
SCHEMBL1992563 0.77 NTRK1 (0.58) JAK2CYP1A2CYP2C19ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP claimed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO claimed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885CYP1A2 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.